Manipal Health IPO: Experts Weigh in on GMP and Investment Prospects
By ETF Desk
The Manipal Health IPO, which aims to raise Rs 4,200 crores, has been met with a mixed response from investors. While some experts believe that the company's strong presence in the healthcare sector and growing demand for medical services make it an attractive investment opportunity, others are cautious due to the high price-to-earnings ratio and concerns about the company's debt burden.
The grey market premium (GMP) for Manipal Health's shares has been fluctuating, with some reports suggesting a GMP of up to Rs 200 per share. However, experts advise investors to exercise caution and not to solely rely on GMP in making investment decisions. A thorough analysis of the company's financials, growth prospects, and market conditions is essential before making an investment call.
According to experts, Manipal Health's strong presence in the healthcare sector, particularly in the southern region of India, is a significant advantage. The company's network of hospitals and clinics is expected to drive growth in the coming years, driven by increasing demand for medical services. However, the high price-to-earnings ratio and concerns about the company's debt burden are potential risks that investors need to consider.
Source: Google News – Manipal.